A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Heart Failure and Preserved Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Heart Failure and Preserved Ejection Fraction

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms PERSPECTIVE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Jul 2021 to 14 Jul 2021.
    • 07 Mar 2017 Planned primary completion date changed from 1 Jul 2021 to 12 Jul 2021.
    • 05 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top